Norbert Bischofberger, Kronos CEO

Gilead­'s ex-R&D chief Bischof­berg­er heads back to the biotech gi­ant to pick up a pair of late-stage drugs that had been put aside

Nor­bert Bischof­berg­er knows en­tosple­tinib well.

Back dur­ing his long, block­buster run as head of R&D at Gilead, re­searchers had once held some high hopes for this drug. But to make it work, he and the team felt it would need a new com­pan­ion di­ag­nos­tic to iden­ti­fy pa­tients. There was talk of a com­bo ap­proach to give it more punch. But the mar­ket was small, mak­ing them won­der if it would be worth go­ing through a lengthy de­vel­op­ment cy­cle to get it through a piv­otal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.